SCHEMBL96460

SCHEMBL96460

CCOC(=O)C(=Cc1ccc(OC)c2c1ccc(=O)n2C)C(=O)OCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.54
LMNA P02545 7/20 0.54
MEN1 O00255 6/20 0.54
KMT2A Q03164 6/20 0.54
POLB P06746 2/20 0.54
PLIN1 O60240 1/20 0.54
PLIN5 Q00G26 1/20 0.54
ABHD5 Q8WTS1 1/20 0.54
NPSR1 Q6W5P4 3/20 0.44
HPGD P15428 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
PKM P14618 2/20 0.44
RAB9A P51151 1/20 0.44
CYP2C19 P33261 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
ALDH1A1 P00352 6/20 0.41
KDM4E B2RXH2 3/20 0.41
CYP3A4 P08684 1/20 0.41
S1PR4 O95977 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL97528 0.75 CYP19A1 (0.49) MAPTHPGDSMN1; SMN2ALDH1A1KDM4E
SCHEMBL98162 0.72 CYP19A1 (0.39) MAPTLMNAKMT2AHPGDSMN1; SMN2
SCHEMBL15248917 0.71 MAPT (0.69) MAPTLMNAMEN1KMT2APOLB
SCHEMBL9494896 0.71 KMT2A (1.00) MAPTLMNAMEN1KMT2APOLB
SCHEMBL11405158 0.70 LMNA (0.68) MAPTLMNAMEN1KMT2APOLB
SCHEMBL8131194 0.70 MAPT (0.68) MAPTLMNAMEN1KMT2APOLB
SCHEMBL14438070 0.70 CYP19A1 (0.61) MAPTNPSR1HPGDSMN1; SMN2ALDH1A1
SCHEMBL11160234 0.69 MAPT (0.66) MAPTLMNAMEN1KMT2APOLB
SCHEMBL97251 0.69 L3MBTL1 (0.40) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL498265 0.67 ALDH1A1 (0.69) MAPTLMNAMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 MAPT 4773/4885LMNA 4860/4885MEN1 3912/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 MAPT 4773/4885LMNA 4860/4885MEN1 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.